Jpmorgan Chase & CO Alkermes Plc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
361Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$806 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$526 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$360 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$351 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$254 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.55B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...